Research programme: narcotic dependency therapeutics - PfizerAlternative Names: CJ 15208
Latest Information Update: 05 Sep 2006
At a glance
- Originator Pfizer
- Mechanism of Action Opioid kappa receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Drug abuse
Most Recent Events
- 05 Sep 2006 Discontinued - Preclinical for Drug abuse (unspecified route)
- 08 Apr 2003 Preclinical trials in Drug abuse (unspecified route)